Price
No data yet.
Social Signal Score
Revenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Tom Frohlich
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 55
- Beta
- 1.49
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 25.93
Financials
Net Income
$-55.77MEBITDA
$-58.91MFree Cash Flow
$-43.66MEPS (diluted)
$-0.76Shares Outstanding (diluted)
61.05M+7630.6%Operating Expenses
$58.91MCash & Debt
$461.20MDividend per Share
$2.40Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-127.41M | $-4.06 |
| 2024 | $0.00 | $-69.63M | $-85.26 |
| 2023 | $0.00 | $-75.52M | $-100.38 |
| 2022 | $0.00 | $-51.51M | $-73.67 |
| 2021 | $0.00 | $-22.96M | $-32.96 |
| 2020 | $0.00 | $-9.61M | $-14.00 |
Valuation
JBIOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80Social Signal Score
Mentions (1)
- Newsseekingalpha.com·5h ago·Negative
Jade Biosciences: Duration Is The Real Product Jade Biosciences (JBIO) targets IgAN with JADE101, aiming for quarterly dosing that could significantly improve patient adherence versus competitors' more frequent regimens. Phase 1 data show JADE101 achieves ~70% IgA reduction with a favorable safety profile; Phase 2 JUNIPER trial interim data expected in 2027 will be pivotal. JBIO's pipeline includes JADE201 (anti-BAFF-R antibody) and JADE301 (IFN-beta inhibitor), both engineered for extended-inte…
View source ↗
Earnings
Thu, Nov 12(in 3 months)
Consensus estimate $-0.73 per share
Typical surprise -9.6% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$-0.76 vs $-0.64miss
- Thu, May 7$-0.57 vs $-0.52miss
- Fri, Mar 6$-0.45 vs $-0.45beat
- Fri, Nov 14$-0.48 vs $-0.57beat
- Thu, Aug 14$-0.86 vs $-0.43miss
- Fri, Apr 25$-12.10 vs $-6.03miss
Estimates and results for JBIO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by JBIO officers and directors.
- Bought
- $44k
- Sold
- —
1 trade
0 trades
- Frohlich Tombought
48 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.